ADMA — ADMA Biologics Share Price
0.000.00%
Last trade - 00:00- $5.08bn
- $5.05bn
- $426.45m
- 74
- 16
- 100
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 26.88 | ||
| PEG Ratio (f) | 24.7 | ||
| EPS Growth (f) | 1.1% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.57 | ||
| Price to Tang. Book | 14.73 | ||
| Price to Free Cashflow | 46.18 | ||
| Price to Sales | 11.92 | ||
| EV to EBITDA | 34.66 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 31.8% | ||
| Return on Equity | 81.65% | ||
| Operating Margin | 32.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 42.22 | 80.94 | 154.08 | 258.21 | 426.45 | 495.23 | 628.73 | 70.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +25793.33 | -12.95 | +39.01 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Directors
- Steven Elms NEC (57)
- Adam Grossman PRE (44)
- Jerrold Grossman VCH (73)
- Brian Lenz CFO (48)
- Young Kwon DRC (49)
- Martha Demski IND (68)
- Bryant Fong IND (48)
- Lawrence Guiheen IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 2nd, 2006
- Public Since
- October 17th, 2013
- No. of Shareholders
- 30,000
- No. of Employees
- 677
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 238,563,612
- Address
- 465 State Route 17, RAMSEY, 07446
- Web
- https://www.admabiologics.com/
- Phone
- +1 2014785552
- Auditors
- KPMG LLP
Upcoming Events for ADMA
ADMA Biologics Inc Annual Shareholders Meeting
ADMA Biologics Inc Annual Shareholders Meeting
Q2 2025 ADMA Biologics Inc Earnings Release
Similar to ADMA
111
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
Avidity Biosciences
NASDAQ Global Market
FAQ
What is the ADMA Biologics share price?
As of Today at 19:05 UTC, shares in ADMA Biologics are trading at $21.31. This share price information is delayed by 15 minutes.
How has the ADMA Biologics share price performed this year?
Shares in ADMA Biologics last closed at $21.31 and the price had moved by +252.81% over the past 365 days. In terms of relative price strength the ADMA Biologics share price has outperformed the S&P500 Index by +231.75% over the past year.
What are the analyst and broker recommendations for ADMA Biologics?
The overall consensus recommendation for ADMA Biologics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ADMA Biologics dividend yield?
ADMA Biologics does not currently pay a dividend.
Does ADMA Biologics pay a dividend?
ADMA Biologics does not currently pay a dividend.
When does ADMA Biologics next pay dividends?
ADMA Biologics does not currently pay a dividend.
How do I buy ADMA Biologics shares?
To buy shares in ADMA Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ADMA Biologics?
As of the previous close price of $21.31, shares in ADMA Biologics had a market capitalisation of $5.08bn.
Where are ADMA Biologics shares listed?
Here are the trading details for ADMA Biologics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ADMA
What kind of share is ADMA Biologics?
Based on an overall assessment of its quality, value and momentum ADMA Biologics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ADMA Biologics share price forecast for 2025?
The analyst consensus target price for shares in ADMA Biologics is $25.27. That is 18.58% above the last closing price of $21.31.
Analysts covering ADMA Biologics currently have a consensus Earnings Per Share (EPS) forecast of $0.71 for the next financial year.
Find out moreWhat is the trend in the ADMA Biologics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ADMA Biologics. Over the past six months, its share price has outperformed the S&P500 Index by +49.65%.
As of the last closing price of $21.31, shares in ADMA Biologics were trading +22.41% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ADMA Biologics PE Ratio?
The ADMA Biologics PE ratio based on its reported earnings over the past 12 months is 26.88. The shares last closed at $21.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ADMA Biologics?
ADMA Biologics' management team is headed by:
- Steven Elms - NEC
- Adam Grossman - PRE
- Jerrold Grossman - VCH
- Brian Lenz - CFO
- Young Kwon - DRC
- Martha Demski - IND
- Bryant Fong - IND
- Lawrence Guiheen - IND